Aspen Surgical Products Acquires Stork® Labor and Delivery Products

Founded in 1958, the Stork line of products includes high-quality, branded sterile disposable obstetric products.

Aspen Surgical Products, Inc. (“Aspen”), a leader in surgical disposable products, announced the acquisition of Stork® (“Stork”), a division of Briggs Healthcare.
Founded in 1958, the Stork line of products includes high-quality, branded sterile disposable obstetric products, such as the Plastibell® Disposable Circumcision Device, the Amnihook® Amniotic Membrane Perforator, the Double-Grip® Umbilical Cord Clamp, the Umbilical Cord Clamp® Clipper, the U-Bag® Pediatric Urine Collection Bag, and the Ready-Rolled® FootPrinter. The acquisition of Stork strengthens Aspen’s broad portfolio of medical and surgical disposables sold into the acute care market.

“The Stork branded products have been a market leader in the labor and delivery space for over 50 years,” said Jason Krieser, CEO of Aspen. “The line fits very well with our current operational and commercial infrastructure, and we believe it is a sound platform for future growth in the obstetrics and gynecology space.”

“Including Stork, we have completed five acquisitions in the last 18 months,” Jason continued. “This, along with our internal manufacturing investments, commercial enhancements, and new product introductions, has helped us improve and expand our portfolio, providing more value to both our distribution partners and our end-user customers.”

 

More

Artificial Intelligence Tools Make Education Materials More Patient Friendly

“Our study shows that widely used large language models have the potential to transform patient education materials into more readable content, which is essential for patient empowerment and better health outcomes,” said Study senior author Jonah Feldman, MD, medical director of transformation and informatics at NYU Langone.

CorWave Completes 6-Month In Vivo Study for Clinical Trials Initiation

In vivo studies demonstrated the pump’s successful operation for a period of up to six months. Additionally, nine chronic ovine implants were conducted for 60 days with no device failure or sign of thrombosis at explant. These significant milestones mark the final stage of CorWave’s preclinical development, paving the way for its First-In-Human study.